On August 10, REMEGEN rose 3.88% in regular trading, trading at 90.5 HKD/share, with turnover of approximately 129 million HKD. The stock continues to benefit from multiple positive catalysts following its mid-year earnings preview.

On the news front, the company previously disclosed its H1 earnings preview, projecting revenue of approximately 58.5 billion yuan, a year-over-year increase of roughly 433%, and net profit attributable to shareholders of approximately 47 billion yuan, turning from a net loss of 4.5 billion yuan in the prior-year period. The dramatic performance improvement was primarily driven by sustained domestic sales growth of core products Telitacicept and Disitamab Vedotin, as well as a significant increase in technology licensing revenue from the exclusive licensing agreement signed with AbbVie for RC148, which carries an upfront payment of 650 million USD and total deal value of up to 5.6 billion USD.

Additionally, the recently published new National Essential Drug List is expected to provide further volume expansion opportunities for the company's key products. The broader biotech sector showed strength, with peers such as 3SBIO up 5.18%, AKESO up 4.0%, and INNOVENT BIO up 2.58%, creating a positive linkage effect.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)